Depression in vascular pathologies: The neurologist's point of view

Vascular Health and Risk Management

Volumn 7, Issue 1, 2011, Pages 433-443

  Moretti, Rita ^a   Bernobich, Elena ^a   Esposito, Francesca ^a   Torre, Paola ^a   Antonello, Rodolfo M ^a   De Angelis, Luisa ^a   Bellini, Giuseppe ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Cardiovascular disease; Cardiovascular risks; Depression; Stressful events

Indexed keywords

ANTIDEPRESSANT AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; COMORBIDITY; DEPRESSION; HUMAN; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; RISK ASSESSMENT; RISK FACTOR;

ANTIDEPRESSIVE AGENTS; CARDIOVASCULAR DISEASES; COMORBIDITY; DEPRESSION; HUMANS; RISK ASSESSMENT; RISK FACTORS;

EID: 84856389389     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S20147     Document Type: Review

References (88)

1. Kaufer D. Treatment of behavioural symptoms in Alzheimer's disease. Annals of Am Acad Neurol. (AAN) CD-version. 2000;5TP.001:7-19.
2. Moretti R, Torre P, Antonello RM, Cazzato G. Behavioural alterations and vascular dementia. Neurologist. 2006;12(1):43-47.
3. Jiang W, Krishnan RRK, O'Connor CM. Depression and heart disease: evidence of a link, and its therapeutic implications. CNS Drugs. 2002;16(2):111-127.
4. Ariyo AA, Haan M, Tangen CM, et al. Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Circulation. 2000;102(15):1773-1779.
5. Bush DE, Ziegelstein RC, Tayback M, et al. Even minimal symptoms of depression increase mortality risk after acute myocardial infarction. Am J Cardiol. 2001;88(4):337-341.
6. Lesperance F, Frasure-Smith N, Talajic MD, Bourassa MG. Fiveyear risk of cardiac mortality in relation to initial severity and one year changes in depression symptoms after myocardial infarction. Circulation. 2002;105(9):1049-1053.
7. Berkman LF, Blumental J, Burg M, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA. 2003;289(23):3106-3116.
8. Swenson JR, O'Connor CM, Barton D, et al. Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Group. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. Am J Cardiol. 2003;92(11):1271-1276.
9. Lett HS, Blumenthal JA, Babyak MA, et al. Depression as a risk factor for coronary artery disease: evidence, mechanism, and treatment. Psychosom Med. 2004;66(3):305-315.
10. Connerney I, Shapiro PA, McLaughlin JS, Bagiella E, Sloan RP. Relation between depression after coronary artery bypass surgery and 12-month outcome: a prospective study. Lancet. 2001;358(9295): 1766-1771.
11. Mallik S, Krumholz HM, Lin ZQ, et al. Patients with depressive symptoms have lower health status benefits after coronary bypass surgery. Circulation. 2005;111(3):271-277.
12. Broadley AJM, Korszun A, Jones CJ, Frenneaux MP. Arterial endothelial function is impaired in treated depression. Heart. 2002;88(5): 521-523.
13. Yamanaka G, Otsuka K, Hotta N, et al. Depressive mood is independently related to stroke and cardiovascular events in a community. Biomed Pharmacother. 2005;59(Suppl 1):S31-S39.
14. Davidson K, Jonas BS, Dixon KE, Markovitz JH. Do depression symptoms predict early hypertension incidence in young adults in the CARDIA study? Arch Intern Med. 2000;160(10):1495-1500.
15. Morris PLP, Robinson RG, Andrzejewski P, Samuels J, Price TR. Association of depression with 10-year post-stroke mortality. Am J Psychiatry. 1993;150(1):124-129.
16. Everson SA, Roberts RE, Goldberg DE, Kaplan GA. Depressive symptoms and increased risk of stroke mortality over a 29-year period. Arch Intern Med. 1998;158(10):1133-1138.
17. Gump BB, Matthews KA, Eberly LE, Chang YF. Depressive symptoms and mortality in men-results from the MRFIT. Stroke. 2005;36(1):98-102.
18. Colantonio A, Kasl SV, Ostfeld AM. Depressive symptoms and other psychosocial factors as predictors of stroke in the elderly. Am J Epidemiol. 1992;136(7):884-894.
19. Thomas C, Kelman HR, Kennedy GJ, et al. Depressive symptoms and mortality in elderly persons. J Gerontol. 1992;47(2):S80-S87.
20. O'Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376(9735):112-123.
21. Paranthaman R, Greenstein AS, Burns AS, et al. Vascular function in older adults with depressive disorder. Biol Psychiatry. 2010;68(2):133-139.
22. Yamashita H, Fujikawa T, Takami H, et al. Long-term prognosis of patients with major depression and silent cerebral infarction. Neuropsychobiology. 2010;62(3):177-181.
23. Wouts L, Janzing JG, Lampe IK, et al. The interaction between cerebrovascular disease and neuroticism in late-life depression: a crosssectional study. Int J Geriatr Psychiatr. 2011;26(7):702-710.
24. Moretti R, Torre P, Antonello RM, Pizzolato G. Subcortical vascular dementia. New York: NovaScience Publishers Inc; 2006.
25. Cummings JL. Frontal subcortical circuits and human behavior. Arch Neurol. 1993, 50(8):873-880.
26. Jorge RE, Starkstein SE, Robinson RG. Apathy following stroke. Can J Psychiatry. 2010;55(6):350-354.
27. Alexopoulos GS, Meyers BS, Young RC, et al. Executive dysfunction and long-term outcomes of geriatric depression. Arch Gen Psychiatry. 2000;57(3):285-290.
28. Alexopoulos GS, Kiosses DN, Murphy C, Heo M. Executive dysfunction, heart disease burden, and remission of geriatric depression. Neuropsychopharmacology. 2004;29(12):2278-2284.
29. Alexopoulos GS, Kiosses DN, Heo M, Murphy CF, Shanmugham B, Gunning-Dixon F. Executive dysfunction and the course of geriatric depression. Biol Psychiatry. 2005;58(3):204-210.
30. Alexopoulos GS, Kiosses DN, Klimstra S, Kalayam B, Bruce ML. Clinical presentation of the "depression-executive dysfunction syndrome" of late life. Am J Geriatr Psychiatry. 2002;10(1):98-106.
31. Alexopoulos GS, Raue P, Arean P. Problem-solving therapy versus supportive therapy in geriatric major depression with executive dysfunction. Am J Geriatr Psychiatry. 2003;11(1):46-52.
32. Krishnan KR, Hays JC, Blazer DG. MRI-defined vascular depression. Am J Psychiatry. 1997;154(4):497-501.
33. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M. 'Vascular depression' hypothesis. Arch Gen Psychiatry. 1997;54(10):915-922.
34. Alexopoulos GS, Meyers BS, Young RC, Kakuma T, Silbersweig D, Charlson M. Clinically defined vascular depression. Am J Psychiatry. 1997;154(4):562-565.
35. Taragano FE, Bagnatti P, Allegri RF. A double-blind, randomized clinical trial to assess the augmentation with nimodipine of antidepressant therapy in the treatment of "vascular depression". Int Psychogeriatr. 2005;17(3):487-498.
36. Otte C, Marmar CR, Pipkin SS, Moos R, Browner WS, Whooley MA. Depression and 24-hour urinary cortisol in medical outpatients with coronary heart disease: the heart and soul study. Biol Psychiatry. 2004;56(4):241-247.
37. Wilbert-Lampen U, Straube F, Trapp A, Deutschmann A, Plasse A, Steinbeck G. Effects of corticotropin-releasing hormone on monocyte function, mediated by CRH-receptor subtype R1 and R2: a potential link between mood disorder and endothelial dysfunction? J Cardiovasc Pharmacol. 2006;47(1):110-116.
38. Rajagopalan S, Brook R, Rubenfire M, Pitt E, Young E, Pitt B. Abnormal brachial artery flow-mediated vasodilatation in young adults with major depression. Am J Cardiol. 2001;88(2):196-198.
39. Wallerath T, Witte K, Schafer SC, et al. Down-regulation of the expression of endothelial NO-synthase is likely to contribute to glucocorticoid-mediated hypertension. Proc Natl Acad Sci U S A. 1999;96(23):13357-13362.
40. Serebrauny V, Glassman AH, Malinin AI, et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitors Sertraline after acute coronary events. The Sertraline Anti-Depressant Heart Attach Randomized Trial (SADHART) Platelet Substudy. Circulation. 2003;108(8):939-944.
41. Chrapko WE, Juracz P, Radomski MW, Lara N, Archer SL, Le Melledo JM. Decreased plasma nitric oxide metabolites and platelet nitric oxide synthase activity in patients with major depression. Biol. Psychiatry. 2004;56(2):129-134.
42. Musselman DL, Marzec UM, Manatunga A, et al. Platelet reactivity in depressed patients treated with paroxetine. Arch Gen Psych. 2000; 57(9):875-882.
43. Murdoch D, Kean SJ. Escitalopram: a review of its use in the management of major depressive disorder. Drugs. 2005;65(16):2379-2404.
44. Escolar G, Diaz-Rcart M, Gomez-Gil E, et al. Serotoninergic mechanisms: a potential link between affective disorders and cardiovascular risk. Drugs Today (Barc). 2005;41(11):721-743.
45. 2+ responses. Blood. 1997;90(7):2615-2625.
46. Laghrissi-Thode F, Wagner WR, Pollock BG, Johnsom PC, Finkel MS. Elevated platelet factor 4 and beta-thromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry. 1997; 42(4):290-295.
47. Lenze EJ, Munin MC, Ferrell RE, et al., Association of the Serotonin transporter gene-like polymorphic region (5-HTTLPR) genotype with depression in elderly patients after hip fracture. Am J Geriatr Psychiatry. 2005;13(5):428-432.
48. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301(5631):386-389.
49. Christiansen LL, Tan QQ, Iachina MM, et al. Candidate gene polymorphisms in the serotonergic pathway: influence on depression symptomatology in an elderly population. Biol Psychiatry. 2007; 61(2):223-230.
50. Jansson M, Gatz M, Berg S, et al. Association between depressed mood in the elderly and a 5-HTR2A gene variant. Am J Med Genet B Neuropsychiatr Genet. 2003;120B(1):79-84.
51. Pollock BG, Ferrell RE, Mulsant BH, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology. 2000;23(5):587-590.
52. Murphy GM Jr, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry. 2004;61(11):1163-1169.
53. Hwang JP, Tsai SJ, Hong CJ, Yang CH, Lirng JF, Yang YM. The Val66Met polymorphism of the brain-derived neurotrophic-factor gene is associated with geriatric depression. Neurobiol Aging. 2006;27(12):1834-1837.
54. Kim JM, Stewart R, Kim SW, et al. Interactions between life stressors and susceptibility genes (5-HTTLPR and BDNF) on depression in Korean elders. Biol Psychiatry. 2007 1;62(5):423-428.
55. Hickie I, Scott E, Naismith S, et al. Late-onset depression: genetic, vascular and clinical contributions. Psychol Med. 2001;31(8):1403-1412.
56. Joutel AA, Corpechot CC, Ducros AA, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature. 1996;383(6602):707-710.
57. Saunders AAM, Hulette OO, Welsh-Bohmer KKA, et al. Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease. Lancet. 1996;348(9020):90-93.
58. Kuller LLH, Shemanski LL, Manolio TT, et al. Relationship between ApoE, MRI findings, and cognitive function in the Cardiovascular Health Study. Stroke. 1998;29(2):388-398.
59. Blazer DG, Burchett BB, Fillenbaum GG. APOE epsilon4 and low cholesterol as risks for depression in a biracial elderly community sample. Am J Geriatr Psychiatry. 2002;10(5):515-520.
60. Kupfer DJ. The pharmacological management of depression. Dialogues Clin Neurosci. 2005;7(3):191-205.
61. El-Damerdash E, Mohamadin AM. Does oxidative stress contribute in tricyclic antidepressants-induced cardiotoxicity? Toxicol Lett. 2004;152(2):159-166.
62. Glassman AH, Johnson LL, Giardina EG, et al. The use of imipramine in depressed patients with congestive heart failure. JAMA. 1983;250(15):1997-2001.
63. Ray WA, Meredith S, Thapa PB, Hall K, Murray KT. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther. 2004;75(3):234-241.
64. Giardina EG, Jonhson LL, Vita J, Bigger JT, Brem RF. Effect of imipramine and nortriptyline on left ventricular function and blood pressure in patients treated for arrhythmias. Am Heart J. 1985;109(5 Pt 1): 992-998.
65. Giardina EG, Barnard T, Johnson LL, Saroff AL, Bigger JT, Louie M. The anti-arrhythmic effect of nortriptyline in cardiac patients with ventricular premature depolarization. JACC. 1986;7(6):1363-1369.
66. Roose SP, Glassman AH. Antidepressant choice in the patient with cardiac disease: lessons from the cardiac arrhythmias suppression trials (CAST) studies. J Clin Psychiatry, 1994;55(Suppl A):83-87.
67. Norman TR, Burrows GD. A risk-benefit assessment of moclobemide in the treatment of depressive disorders. Drug Safety. 1995;12(1): 46-54.
68. Roose SP, Glassman AH, Attia E, Woodring S, Giardina EG, Bigger JT. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry. 1998;155(5):660-665.
69. Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288(6):701-709.
70. Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation. 2003;108(1):32-36.
71. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet. 1997; 32(Suppl 1):1-21.
72. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1999;148(6): 705-713.
73. Rosner MH. Severe hyponatremia associated with the combined use of thiazide diuretics and selective serotonin reuptake inhibitors. Am J Med Sci. 2004;327(2):109-111.
74. Alvarez W, Pickworth KK. Safety of antidepressant drugs in the patients with cardiac disease: a review of the literature. Pharmacotherapy. 2003;23(6):754-771.
75. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry. 1998;59(10):502-508.
76. Montgomery SA. The place of milnacipran in clinical practice. Int Clin Psychopharmacol. 2003;18(Suppl 1):1-9.
77. Thase ME, Tran PV, Wiltse C, Pangallo BA, Mallinkrodt C, Detke MJ. Cardiovascular profile of duloxetine, a dual reuptake inhibitor on serotonin and norepinephrine. J Clin Psychopharmacol. 2005;25(2): 132-140.
78. Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005;10(9):732-747.
79. Nicholas LM, Ford AL, Esposito SM, Ekstrom RD, Golden RN. The effects of mirtazepine on plasma lipid profiles in healthy subjects. J Clin Psychiatry. 2003;64(8):883-889.
80. Troncoso AL, Gill T. Hypertensive urgency with clonidine and mirtazapine. Psychosomatics. 2004;45(5):449-450.
81. Ferini-Strambi L, Manconi M, Castronovo V, Riva L, Bianchi A. Effects of reboxetine on sleep and nocturnal cardiac autonomic activity in patients with dysthymia. J Psychopharmacol. 2004;18(3):417-422.
82. Rampello L, Alvano A, Chiechio S, Raffaele R, Vecchio I, Malaguarnera M. An evaluation of efficacy and safety of reboxetine in elderly patients, affected by "retarded" post-stroke depression. A random, placebocontrolled study. Arch Gerontol Geriatr. 2005;40(3):275-285.
83. Van der Merwe TJ, Silverstone T, Ankier SI, Warrington SJ, Turner P. A double-blind non-crossover placebo-controlled study between group comparison of trazodone and amitryptline on cardiovascular function in major depressive disorder. Psychopathology. 1984;17(Suppl 2):64-76.
84. Winkler D, Ortner R, Pjrek E, Aschauer H, Kasper S. Trazodone-induced cardiac arrhythmias: a report of two cases. Hum Psychopharmacol. 2006:21(1):61-62.
85. Munizza C, Olivieri L, Di Loreto G. Dionisio P. A comparative randomized double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder. Curr Med Res Opin. 2006; 22(9):1703-1713.
86. Millan MJ. Serotonin 5HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005;60(5):441-460.
87. Robinson DS, Roberts LD, Smith JM, et al. The safety profile of nefazodone. J Clin Psychiatry. 1996;57(Suppl 2):31-38.
88. Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, Giardina EG. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry. 1991;148(4):512-516.